Which Hedge Fund is Animating Achillion?

QVT Financial, a hedge fund managed by Daniel Gold, specializes in healthcare-related stocks, holding about half of its equity portfolio in biotech and pharmaceutical stocks. According to its 13F filing, as of the end of June 2012, the fund’s top holdings included VIVUS, Inc. (NASDAQ:VVUS), Medivation, Inc. (NASDAQ:MDVN), and TPC Group Inc (NASDAQ:TPCG), all of which have had break-out years, returning 80 percent of more (view Gold’s portfolio here).

Most recently, QVT struck a deal with Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), purchasing 6.38 million shares valued at $41 million in total. The company is yet to start generating revenue from its flagship products, but late-phase drugs are on tap in the company’s pipeline. The direct offering will help improve the balance sheet for the company as it progresses through a number of late-stage drug trials.

Achillion Pharmaceuticals, Inc.

Hepatitis C has been a major source of interest for the company and is an area which has been surrounded by a number of mergers and acquisitions. Roche Holding Ltd. (PINK:RHHBY) acquired Anadys Pharmaceuticals Inc. for $230 million, Gilead Sciences, Inc. (NASDAQ:GILD) acquired Pharmasset Inc. $11 billion, and Bristol Myers Squibb Co. (NYSE:BMY) purchased Inhibitex Inc. for $2.5 billion. Achillion is the smallest significant company with an orally-administered hepatitis C therapy in the works.

Many consider Gilead Sciences, Inc. to have a substantial leg up, however, with its Pharmasset acquisition. The clinical trial results for GS-7977, an orally administered hepatitis C medication, have been very positive. This drug is thought to be a sign that Gilead Sciences will develop an interferon-free hepatitis C therapy regimen before long. (Many immunological drugs require interferon administration—a chemical that usually has diffuse and often deleterious effects on patients.) GS-7977 is already known to be effective with a 12-week interferon administration.

However, Achillion also has much to offer here. QVT likely bought the company primarily because it is the most promising orphan yet to be purchased by large-cap pharma. As a background to these drug developments, hepatitis C works by producing a core protein and three other proteins, NS3, NS4, and NS5. The strategy from Achillion is to neutralize the actual viral protein products, so the company has developed proteases—drugs that destroy these proteins. The NS3 protease inhibitor sovaprevir (ACH-1625), one of Achillion’s hepatitis C therapies, is in phase II clinical trials. An NS5A inhibitor, ACH-3102, has shown promising phase I results. Piper Jaffray analyst Ted Tenthoff remarked that “Achillion has potentially best-in-class HCV protease and NS5A inhibitors, offering a counter play to the nuc[lease]-dominated regimens” than Gilead Sciences is pursuing (nucleases targets the genetic material that codes for these proteins, which is a different tactic).

Since Bristol Myers has exited the hepatitis C space (its Inhibitex acquisition flopped), Gilead and Achillion stand to be significant beneficiaries. This set-up makes Achillion a competitive acquisition candidate. However, the Inhibitex flop might be something of a warning to other companies looking to slurp up an unproven hepatitis C drug company.

This small-cap pharmaceutical company has a number of balance sheet virtues. It carries practically no debt as a percent of equity, and at the end of 2011, the company had $80 million in cash and cash equivalents on hand. Obviously, a large store of cash is critical for any biotech or pharmaceutical stock: seeing products through clinical testing rounds requires a multi-year store of cash. The new direct offering to QVT ups the total cash reserves for Achillion to over $100 million.

We like watching hedge fund activity especially when a company is at the mercy of product cycles, patent approvals, and clinical trials—things that insiders have a leg up on. So Achillion is an interesting idea for as a high-growth pharmaceutical pick. Insider information in a situation like this is something of an assurance given the fickle outcomes in small-cap pharma.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!